Wedbush Raises Price Target for Viridian Therapeutics (NASDAQ: VRDN) Following Lumvoa FDA Approval
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameSentinelOne Inc.
-
Registration countryUSA
-
IndustryIT Services and Computer Programming
-
М/S&P/F
*** /*** /***









